NBA Fearless Forecast Weekly Rank: 58
NBA Fearless Forecast Weekly Rank: 58
Ghana began its coronavirus vaccination drive on Tuesday with 600,000 AstraZeneca doses it received from the global COVAX vaccine-sharing facility aimed at providing shots to developing nations to help combat the COVID-19 pandemic. People lined up for shots outside the regional hospital in the capital, Accra, for a first phase of vaccinations which will prioritise frontline health workers and others at high risk. While western nations have secured millions of doses and launched mass vaccination drives, most poorer countries do not yet have access to any, raising concerns about equitable distribution of vaccines to fight the pandemic.
CoreSite Realty Corporation (NYSE:COR) (the "Company"), a premier provider of secure, reliable, high-performance data center, cloud access and interconnection solutions across the U.S., and a VMware Technology Alliance Partner, today announced the availability of VMware® Cloud™ on Dell EMC®. This fully managed infrastructure as a service offering is available across CoreSite’s national platform of enterprise-class, cloud-enabled data center campuses. CoreSite and VMware have created a Center of Excellence, technical validation proof of concept (PoC) lab, to accelerate innovation and cost savings for enterprises challenged with today’s escalating capital IT expenses, while also enabling emerging requirements of low-latency applications and data sovereignty management. The solution also future proofs enterprises for tomorrow’s AI, machine-learning, IoT and 5G use cases.
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s ability to obtain regulatory approval for BCV; the timing and receipt of a potential procurement contract for BCV in smallpox; and the timing of enrollment in the DSTAT trial for AML. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that BCV may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; risks related to the timing and conduct of the DSTAT trials for AML and COVID; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT:Investor Relations: Michelle LaSpaluto919 email@example.comWill O’ConnorStern Investor Relations212firstname.lastname@example.org
GreenPath Financial Wellness and eGain have launched the Virtual Financial Coach™, a unique, turnkey solution for financial counseling automation
Deal gives GTreasury fully-integrated netting technology to meet growing customer demand for global netting and reconciliation capabilitiesCHICAGO, March 02, 2021 (GLOBE NEWSWIRE) -- GTreasury, a treasury and risk management platform provider, today announced the acquisition of Coprocess, the leading provider of intercompany netting solutions. Adding intercompany netting to the GTreasury platform and ecosystem gives corporate treasurers the ability to significantly streamline their settlement processes, cut costs by reducing payments and FX volumes, and add new automated efficiencies into their treasury workflows. “GTreasury continues to look for ways to empower corporate treasurers to do their jobs more effectively, more efficiently, and with less cost to their organizations,” said Renaat Ver Eecke, CEO, GTreasury. “The complexities of doing business across countries and across banks continues to grow, and the technologies that treasurers rely on must keep up with that pace. Acquiring Coprocess does exactly that for our clients. Coprocess brings expertise in multilateral netting that is second to none, and we’re extremely excited to welcome the Coprocess team, learn from them, and jointly build new and fully integrated solutions that will directly benefit our customer base.” Treasurers using Coprocess regularly see payments and FX volumes lowered by as much as 70%, while also benefiting from more centralized banking relationships and reduced float and complexity. Real-time intercompany reconciliation capabilities deliver visibility into intercompany transactions, interest, loans and treasury transactions – eliminating mismatches and facilitating automatic reporting. Fully centralized vendor payments further simplify often-costly and time-intensive treasury operations. The Coprocess solution is also highly configurable to businesses’ unique netting processes and organizational structures, and easily incorporates into treasurers’ existing architectures. Combining the leading netting system with GTreasury’s extensive cash, payments, FX, and risk management capabilities provides treasurers with an extensive, easy-to-use, and end-to-end solution for optimizing their treasury processes and workflows. The acquisition also continues to build the momentum of the GTreasury platform. “We saw record transaction volume flow though our treasury management ecosystem in 2020,” said Ver Eecke. “To continue to meet our clients’ needs, we’ve been signing key partnerships with banks and complementary technology providers, expanded our platform through new innovations like SmartPredictions™, our AI-fueled cash forecasting, and executed on strategic acquisitions such as with Visual Risk and now Coprocess.” Founded in 1991, Coprocess has established itself as the leading intercompany netting provider. The company’s 175 global clients across a range of industries leverage the Coprocess solution to net millions of invoices per year and save hundreds of thousands of dollars in FX and transaction expenses. “Like Coprocess, GTreasury has long been a trusted technology partner to organizations around the world,” said Andrew Goldie, CEO, Coprocess. “They understand that continual innovation is critical to ensuring treasurers can do their jobs faster, with more accurate foresight, and as cost-efficiently to their businesses as possible. We share these aims, and look forward to a great future for Coprocess within GTreasury. We are excited to put our comprehensive netting solution into the hands of more treasurers.” About GTreasury For more than 30 years, GTreasury has delivered the leading digital Treasury and Risk Management System (TRMS) to corporate treasurers across industries. With its continually innovating Software-as-a-Service platform, GTreasury provides customers with a single source of truth for all their cash, payments, and risk activities. The TRMS solution offers any combination of Cash Management, Payments, Financial Instruments, Risk Management, Accounting, Banking, and Hedge Accounting – seamlessly integrated, on-demand worldwide and fully secured. Headquartered in Chicago with offices serving EMEA (London) and APAC (Sydney and Manila), GTreasury’s global community includes more than 800 customers and 30+ industries reaching 160+ countries worldwide. ContactBret Clementbret@clementpeterson.com
-- Third quarter achievements include two FDA approvals and commercialization agreements in prostate cancer and women’s healthLONDON and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- — Sumitovant Biopharma. today announced that its five subsidiary healthcare companies (Myovant, Urovant, Enzyvant, Altavant and Spirovant ) achieved multiple clinical and corporate milestones in the company’s third quarter ending on December 31, 2020. “The Sumitovant family of companies continue to advance our pipeline with two FDA approvals, a global commercialization and development collaboration, clinical progress and recognition for one of our CEOs as a visionary company leader,” said Myrtle Potter, CEO of Sumitovant Biopharma. “We are pleased to see so much progress in Sumitovant’s third quarter of operation.” Regulatory and Clinical Highlights On December 18, 2020, the FDA approved Myovant’s ORGOVYXTM(relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX is the US first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for advanced prostate cancer. On December 23, 2020, the FDA approved Urovant’s GEMTESA® (vibegron) for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency. On November 24, 2020, Urovant Sciences announced topline data from its Phase 2a study of vibegron for the treatment of irritable bowel syndrome (IBS) pain that did not meet its primary endpoint. On October 21, 2020, Myovant presented additional data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in endometriosis and uterine fibroids at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress. Corporate Highlights On December 28, 2020, Myovant announced a collaboration with Pfizer in the US and Canada in women’s health plus an option for ex-US minus certain Asian countries in prostate cancer. The companies will jointly develop and commercialize ORGOVYX in advanced prostate cancer and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women’s health including uterine fibroids and endometriosis. On November 12, 2020, Sumitovant Biopharma and Urovant Sciences announced Sumitovant’s planned acquisition of the remaining stake in Urovant Sciences that it does not currently own. On October 13, 2020, Spirovant CEO Joan Lau was named Entrepreneur of the Year in Greater Philadelphia by Ernst & Young. On October 7 2020, Spirovant CEO Joan Lau was named a Woman of Distinction by the Philadelphia Business Journal. About Sumitovant Biopharma Ltd. Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences. Myovant has one FDA-approved medicine, ORGOVYX for adult patients with advanced prostate cancer. Urovant has one FDA-approved medicine, GEMTESA 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence. Sumitovant’s promising pipeline is comprised of early-through late-stage investigational medicines across a range of disease areas targeting high unmet need. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. For further information about Sumitovant, please visit https://www.sumitovant.com. Follow Sumitovant on LinkedIn. About Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com. About Myovant Sciences Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Myovant’s lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit Myovant’s website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn. About Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH). The Company’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com. Forward-Looking Statements This press release contains forward-looking statements that are based on management’s assumptions and beliefs in light of information available up to the day of announcement and thus involve both known and unknown risks and uncertainties. Actual financial results and other situations of the future may differ materially from those presented in this press release due to various factors. For more information with respect to Myovant Sciences, including disclosure regarding the risks and uncertainties related to any forward-looking statements, please refer to Myovant Sciences’ filings with the United States Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Myovant Sciences’ Quarterly Report on Form 10-Q filed on February 10, 2020, as such risk factors may be amended, supplemented or superseded from time to time. For more information with respect to Urovant Sciences, including disclosure regarding risks and uncertainties related to any forward-looking statements, please refer to Urovant Sciences’ filings with the United States Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q filed with the SEC, as such risk factors may be amended, supplemented or superseded from time to time by other filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. These forward-looking statements are based on information available to Urovant as of the date of this press release and speak only as of the date of this release. Urovant disclaims any obligation to update these forward-looking statements, except as may be required by law. This press release contains “forward-looking statements” concerning the development and commercialization of Altavant’s products, the company’s business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Altavant undertakes no obligation to update any forward-looking statements for any reason. CONTACT: Mary Stutts Sumitovant Biopharma 707-373-0097 email@example.com
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021. A webcast of the presentation will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event. About Athira Pharma, Inc.Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram. Investor & Media Contact:Julie RathbunAthira PharmaJulie.firstname.lastname@example.org
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered KT-474 in healthy volunteers, as well as in patients with atopic dermatitis or hidradenitis suppurativa WATERTOWN, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company recently initiated dosing in the single ascending dose (SAD) portion of the Phase 1 clinical trial evaluating KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. KT-474 is a potential first-in-class, highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis and potentially other indications. “We are excited to initiate dosing in the SAD portion of the Phase 1 trial of KT-474, marking the first time that a heterobifunctional small molecule degrader has ever been administered to healthy volunteers,” said Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics. “Atopic dermatitis, hidradenitis suppurativa and rheumatoid arthritis collectively impact millions of people in the U.S. alone, and we believe our novel approach of degrading IRAK4 with KT-474 offers the potential to improve outcomes over current treatment options. We look forward to our next milestone of establishing safety, on-target pharmacology, and mechanistic proof-of-concept with KT-474 in healthy volunteers later this year.” The first-in-human Phase 1 trial is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. Additional information on this clinical trial can be found on www.clinicaltrials.gov. “KT-474 is the first heterobifunctional protein degrader candidate to advance into the clinic for immune-inflammatory conditions, representing a significant achievement for Kymera and an important milestone for the whole field of targeted protein degradation,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “I am proud of the progress that our R&D organization has made to advance our first program into the clinic in only four years, and we are looking forward to the initiation of our IRAKIMiD and STAT3 Phase 1 oncology trials in 2021, setting up a transformational year for Kymera.” About IRAK4 and KT-474 IRAK4 is a key protein involved in inflammation mediated by the activation of TLRs and IL-1Rs. Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions. KT-474 is designed to block TLR/IL-1R-mediated inflammation more broadly compared to monoclonal antibodies targeting single cytokines and enable pathway inhibition that is superior to IRAK4 kinase inhibitors by abolishing both the kinase and scaffolding functions of IRAK4. Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields. About Pegasus™Pegasus™ is Kymera Therapeutics’ proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools. About Kymera TherapeuticsKymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company’s planned interactions with regulatory authorities, including the resolution of the current partial clinical hold for KT-474; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended September 30, 2020, filed on November 5, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor Contact:Paul CoxVP, Investor Relations and Communicationspcox@kymeratx.com917-754-0207 Media Contact:Lissette L. SteeleVerge Scientific Communications for Kymera Therapeuticslsteele@vergescientific.com 202-930-4762
Talenom Plc, Press release, 2 March 2021 at 14:00 EET Talenom has a new office in Ivalo Talenom Plc has acquired Tilipalvelu Pirkko Kemppainen Oy's accounting business in Ivalo on 1 March 2021. Tilipalvelu Pirkko Kemppainen Oy is an Ivalo-based full-service accounting company established in 1987. The company has a branch office in Rovaniemi. The company is the northernmost authorised accounting company in Finland. The total sales of the acquired business transferred to Talenom amount to around 0.4 million euros. In addition to the entrepreneur family, the company has two employees. The company's entire personnel will be transferred to Talenom in connection with the acquisition. "Tilipalvelu Pirkko Kemppainen Oy has strong local knowledge of companies in the Northern Lapland region and special expertise in tourism and construction industries. By combining these strengths and Talenom's software and service development, we can be an easy, reliable and long-term accounting partner for local entrepreneurs," says Otto-Pekka Huhtala, CEO of Talenom. "As a family business, we have been looking for the best alternative for continuing our business when the time comes for us to step aside. The transaction will enable us to implement a generational change while gaining access to Talenom's expertise and resources. Talenom's own software enables the provision of electronic financial management services cost-effectively to even the smallest customers, which we considered important. Modern solutions also open up opportunities for the development of reporting and advisory services," comment Pirkko Kemppainen, Arto Appelgren and Otto Appelgren, the entrepreneurs of Tilipalvelu. The business acquisition does not have any significant impact on Talenom’s financial position or future outlook in the short term.TALENOM PLC Further information: Otto-Pekka HuhtalaCEOTalenom Plctel. +358 40 703 8554 Talenom is an agile and progressive accounting firm established in 1972. Our business idea is to make day-to-day life easier for entrepreneurs with the easiest-to-use digital tools on the market and highly automated services. In addition to comprehensive accounting services, we support our customers’ business with a wide range of expert services as well as financing and banking services. Our vision is to provide unbeatable accounting and banking services for SMEs. Talenom has a history of strong growth – the average annual increase in net sales was approximately 15.5% between 2005 and 2020. At the end of 2020, Talenom had 912 employees in Finland and Sweden at a total of 47 locations. Talenom’s share is quoted on the main list of the Helsinki Stock Exchange. DISTRIBUTION:Main mediawww.talenom.fi
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference (March 9-10, 2021)A fireside chat with Sue Washer, President & Chief Executive Officer, will be available to view on-demand beginning Tuesday, March 9, 2021 at 7:00 a.m. ET through the entirety of the conference. 33rd Annual ROTH Conference (March 15-17, 2021)Ms. Washer and Mark Shearman, Chief Scientific Officer, will participate in a fireside chat at 1:00 p.m. ET on Monday, March 15, 2021. Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events. About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. IR/PR CONTACTS: David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) email@example.com or firstname.lastname@example.org Corporate Contacts:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728 email@example.com Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) firstname.lastname@example.org
Kohl’s Corporation (NYSE:KSS) today reported results for the quarter and year ended January 30, 2021.
Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the intellectual property of ketamine in the treatment amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease. The University of Kansas Medical Center inventors Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery that ketamine can be administered as an effective treatment for ALS. Their preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and increases life expectancy when given in the early stages of muscle decline. Currently, there is no known cure for ALS. ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. Peak sales for a new drug to treat ALS can achieve over USD $1 billion. ALS is a progressive neuromuscular disease with a life expectancy of only 2 to 6 years after diagnosis. As ALS advances, upper and lower motor neurons die causing the brain to lose its ability to control muscle movement. ALS patients experience progressive loss of voluntary muscle action as an effect of the disease, resulting in the inability to speak, eat, move and, eventually, breathe. Thus far, only three pharmaceuticals have been approved by the FDA for the treatment of ALS: riluzole, edaravone, and most recently, Nuedexta (dextromethorphan HBr and quinidine sulfate). These drugs are effective against disease mechanisms of ALS but fail to have measurable effects on attenuating disease progression or improve survival. Therefore, there is an imperative need for new pharmacological therapies that can stop or slow the muscle decline associated with ALS progression and extend life expectancy of the ALS patient. Ketamine has the potential to effectively increase life expectancy of those with ALS at any stage and slow the progressive loss of muscle associated with poor outcomes of the disease. Ketamine works by blocking the action of the ionotropic glutamate receptor, the NMDA receptor. Unlike other inhibitors of NMDA receptor function, such as riluzole, ketamine dampens NMDA receptor-related glutamate excitotoxicity indirectly. Further, ketamine can lower D-serine concentrations intracellularly and also partially activates dopamine receptors. Collectively, these mechanisms of ketamine contribute in part to the drug’s neuroprotective effects which may extend to the motor neurons targeted in ALS. PharmaTher will seek FDA approval for orphan drug designation of ketamine in the treatment of ALS and will advance towards an FDA investigational new drug application to conduct a Phase II clinical study this year. “We are pleased to have added the Lou Gehrig’s disease program to our already impressive development pipeline that focuses on novel uses, formulations and delivery of ketamine in the treatment of neuropsychiatric, neurological and neuromuscular diseases,” said Fabio Chianelli, CEO of PharmaTher. Under the terms of the Agreement, PharmaTher gained exclusive worldwide development and commercial rights to provisional patent no. 63/025,778 titled Ketamine to Extend Survival after Muscle Wasting in Amyotrophic Lateral Sclerosis. Consistent with industry standards, PharmaTher paid a one-time fee for entering into the Agreement, and all other future payments will be based on clinical trial and revenue milestones reached by PharmaTher. About PharmaTher Inc. PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat neuropsychiatric, neurological and neuromuscular diseases. Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn. For more information, please contact: Fabio ChianelliChief Executive OfficerPharmaTher Inc.Tel: 1-888-846-3171Email: email@example.comWebsite: www.pharmather.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of November 30, 2020 (“MD&A”), dated January 27, 2021, which is available on the Company’s profile at www.sedar.com. This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning its February 2021 natural gas sales and drilling program. Gas Sales Averaged 187 MMscfpd for February 2021 Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 187 million standard cubic feet per day (“MMscfpd”) for February 2021, a 6% increase from average gas sales of 177 MMscfpd for the month of January 2021. Flauta 1 and Oboe 2 The Flauta 1 exploration well which completed drilling in February 2021 did not encounter commercial gas and has been plugged and abandoned. The Oboe 2 development well has been completed as a successful gas producer and is being tied into the Jobo gas processing facility. The rigs are currently being mobilized to drill the Cañahuate 4 development well and the Milano 1 exploration well, both of which are anticipated to spud the second week of March 2021. Each will take approximately 5 weeks to drill and test. About Canacol Canacol is a natural gas exploration and production company with operations focused in Colombia. The Corporation's common stock trades on the Toronto Stock Exchange, the OTCQX in the United States of America, and the Colombia Stock Exchange under ticker symbol CNE, CNNEF, and CNE.C, respectively. This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur, including without limitation statements relating to estimated production rates from the Corporation's properties and intended work programs and associated timelines. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation cannot assure that actual results will be consistent with these forward-looking statements. They are made as of the date hereof and are subject to change and the Corporation assumes no obligation to revise or update them to reflect new circumstances, except as required by law. Prospective investors should not place undue reliance on forward looking statements. These factors include the inherent risks involved in the exploration for and development of crude oil and natural gas properties, the uncertainties involved in interpreting drilling results and other geological and geophysical data, fluctuating energy prices, the possibility of cost overruns or unanticipated costs or delays and other uncertainties associated with the oil and gas industry. Other risk factors could include risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities, and other factors, many of which are beyond the control of the Corporation. Realized contractual gas sales is defined as gas produced and sold plus gas revenues received from nominated take or pay contracts. CONTACT: For more information please contact: Investor Relations South America: +571.621.1747 IR-SA@canacolenergy.com Global: +1.403.561.1648 IR-GLOBAL@canacolenergy.com http://www.canacolenergy.com
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 OTL-200 U.S. Filing Strategy for Metachromatic Leukodystrophy (MLD) Expected by Mid-2021 R&D Organizational Leadership Changes Announced BOSTON and LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the year ended December 31, 2020, as well as recent accomplishments, 2021 strategic priorities and upcoming milestones, and related organizational leadership updates. Frank Thomas, president and chief operating officer said, “It is gratifying to witness the positive momentum Orchard has already established in early 2021 driven by solid execution. Our compelling data in neurodegenerative disorders at the WORLDSymposium and successful completion of the $150 million financing exemplify this recent progress and showcase a growing appreciation for the potential of HSC gene therapy. We look forward to continuing our work in the year ahead and delivering further benefit for patients and our shareholders." Recent Accomplishments February 2021 Executed a $150 million private investment in public equity (PIPE) financing at a price of $6.22 per share with several existing and new investors with expertise in healthcare, including RA Capital Management, Avidity Partners, Casdin Capital, Farallon Capital, and Surveyor Capital (a Citadel company), among others. The link to the full release is available here.Presented data from multiple neurometabolic programs at the 2021 WORLDSymposium. The link to the full release is available here. Interim data for OTL-203 showing positive clinical results in multiple disease manifestations of MPS-IH was highlighted. All eight patients treated with OTL-203 showed stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment. Treatment with OTL-203 has been generally well-tolerated with a safety profile consistent with the selected conditioning regimen.An oral presentation featuring supportive biomarker data from the first three patients in the ongoing OTL-201 POC study for mucopolysaccharidosis type IIIA (MPS-IIIA, or Sanfilippo syndrome) was also featured. The treatment has been generally well-tolerated in the first three patients with no treatment-related serious adverse events (SAEs), and all transplant-related SAEs and adverse events have resolved. January 2021 Appointed Braden Parker as chief commercial officer. Mr. Parker most recently served as Orchard’s senior vice president and general manager for North America and has more than 20 years of experience in the healthcare industry, including commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s U.S. product launch in Duchenne muscular dystrophy and oversaw strategic planning for the gene therapy business.Received Regenerative Medicine Advanced Therapy (RMAT) designation for OTL-200 from the U.S. Food and Drug Administration (FDA) for early-onset MLD. This designation has the potential to enhance regulatory interactions in the U.S. and open an expedited path to a biologics license application (BLA) filing.Secured partnerships with two leading regional specialty pharmaceutical companies to broaden access to Libmeldy (OTL-200) for eligible patients with MLD in the Middle East & Turkey. 2021 Corporate Priorities and Upcoming Milestones Orchard previously outlined the following key corporate objectives and upcoming expected milestones: Build a successful commercial business in hematopoietic stem cell (HSC) gene therapy Launch Libmeldy (OTL-200) for the treatment of eligible patients with early-onset MLD in Europe in the first half of 2021Complete additional interactions with the FDA by mid-2021 to determine the path to a BLA filing for OTL-200File an Marketing Authorization Application (MAA) for OTL-103 in Wiskott-Aldrich syndrome (WAS) with the European Medicines Agency by year-end 2021; followed by a BLA filing in the U.S. in 2022 Continue to lead the development of gene therapies for neurodegenerative disorders by advancing two POC programs in MPS-IH and MPS-IIIA Initiate a registrational trial for OTL-203 for MPS-IH by year-end 2021Complete enrollment in the five-patient POC trial for OTL-201 for MPS-IIIAPresent additional clinical data from the OTL-203 and OTL-201 POC trials Investigate the potential of HSC gene therapy in larger indications Announce new preclinical data from research programs in frontotemporal dementia with progranulin mutations (GRN-FTD) and Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD) in the second half of 2021 Organizational Leadership Updates Given the progress on key development programs, Anne Dupraz has been appointed to the expanded role of chief development officer. In addition to overseeing the company’s regulatory strategy, Ms. Dupraz will lead product development with the goal of ensuring a seamless approach to moving Orchard’s programs through to potential regulatory approval. Ms. Dupraz possesses more than 20 years of experience in the clinical and regulatory fields and has deep expertise in advanced therapies, having been involved in more than 50 different tissue, cell and gene-based therapy development programs in her career. Ran Zheng, chief technical officer, and Andrea Spezzi, chief medical officer, are stepping down from their respective leadership positions with Orchard to pursue other opportunities. Orchard has initiated a global search for permanent replacements for both of these roles. Fourth Quarter 2020 Financial Results Research and development expenses were $22.6 million for the three months ended December 31, 2020, compared to $30.9 million in the same period in 2019. R&D expenses include the costs of clinical trials and preclinical work on the company’s portfolio of investigational gene therapies, as well as costs related to regulatory, manufacturing, license fees and milestone payments under the company’s agreements with third parties, and personnel costs to support these activities. The company expects R&D expenses to grow slightly in the upcoming periods as the company continues to advance its programs through later stages of development. Selling, general and administrative expenses were $16.2 million for the three months ended December 31, 2020, compared to $18.5 million in the same period in 2019. The decrease was primarily due to realization of savings associated with an updated strategy and corporate restructuring announced in May 2020. Net loss attributable to ordinary shareholders was $33.6 million for the three months ended December 31, 2020, compared to $45.4 million in the same period in 2019. The decline in net loss as compared to the prior year was primarily due to savings realized in our operating expenses as a result of the company’s updated strategy and corporate restructuring. The company had 98.3 million ordinary shares outstanding as of December 31, 2020. Thomas continued, "Our burn rate has declined from prior periods as we see the positive impact of our May 2020 corporate restructuring take hold, providing a longer runway and greater financial flexibility, aided by our recent financing. We are investing to support execution for the highest value programs in our portfolio while also dedicating capital to our longer-term strategy to expand into larger indications. Cash, cash equivalents and investments as of December 31, 2020, were $191.9 million compared to $325.0 million as of December 31, 2019, with the decrease primarily driven by cash used to fund operations in 2020. In the fourth quarter of 2020, the cash used to fund operations was approximately $12.0 million after the receipt of approximately $19.2 million from R&D tax credit refunds related to 2019 qualifying activities under the tax code in the UK. The company expects that its cash, cash equivalents and investments as of December 31, 2020, along with gross proceeds of $150.0 million from the February 2021 private placement, will support its currently anticipated operating expenses and capital expenditure requirements into the first half of 2023. This cash runway excludes the $50 million available under the company’s credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future potential U.S. approvals. About Libmeldy / OTL-200Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD.The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US. Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn. Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-Looking Statements This press release contains certain forward-looking statements about Orchard’s strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchard’s product candidates, including the product candidates referred to in this release, Orchard’s expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchard’s financial condition and cash runway into the first half of 2023. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchard’s product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates; the delay of any of Orchard’s regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchard’s product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchard’s ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchard’s product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchard’s business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchard’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Consolidated Statements of Operations Data(In thousands, except share and per share data)(Unaudited) Three months ended December 31, 2020 2019 Product sales, net$— $595 Costs and operating expenses: Cost of product sales — 191 Research and development 22,648 30,899 Selling, general and administrative 16,226 18,531 Total costs and operating expenses 38,874 49,621 Loss from operations (38,874) (49,026)Other income (expense): Interest income 279 1,843 Interest expense (575) (633)Other income, net 5,635 2,533 Total other income, net 5,339 3,743 Net loss before income tax (33,535) (45,283)Income tax expense (85) (133)Net loss attributable to ordinary shareholders$(33,620) $(45,416) Consolidated Balance Sheet Data(in thousands)(Unaudited) December 31,December 31, 2020 2019 Assets Current assets: Cash and cash equivalents $55,135$19,053 Marketable securities 136,813 305,937 Trade receivables 878 1,442 Prepaid expenses and other current assets 13,365 8,530 Research and development tax credit receivable, current 17,344 14,934 Total current assets 223,535 349,896 Non-current assets: Operating lease right-of-use assets 29,815 19,415 Property and equipment, net 4,781 7,596 Research and development tax credit receivable — 13,710 Other long-term assets 22,806 8,664 Total non-current assets 57,402 49,385 Total assets $280,937$399,281 Liabilities and shareholders' equity Current liabilities: Accounts payable $8,823$11,984 Accrued expenses and other current liabilities 28,943 37,980 Operating lease liabilities 8,934 5,892 Notes payable, current 4,861 — Total current liabilities 51,561 55,856 Notes payable, long-term 20,204 24,699 Operating lease liabilities, non-current 24,168 15,320 Other long-term liabilities 6,570 4,213 Total liabilities 102,503 100,088 Shareholders’ equity: 178,434 299,193 Total liabilities and shareholders’ equity $280,937$399,281 Contacts InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com MediaChristine HarrisonVice President, Corporate Affairs+1 firstname.lastname@example.org
New York, NY, March 02, 2021 (GLOBE NEWSWIRE) -- Kaltura, Inc., the video experience cloud, today announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Kaltura has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol “KLTR.” Goldman Sachs & Co. LLC and BofA Securities are acting as lead book-running managers for the proposed offering. Wells Fargo Securities and Deutsche Bank Securities are also acting as book-running managers for the proposed offering. Canaccord Genuity LLC, JMP Securities, KeyBanc Capital Markets, Needham & Company and Oppenheimer & Co. Inc. are acting as co-managers for the proposed offering. The proposed offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526, or by email at email@example.com or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at firstname.lastname@example.org. A registration statement on Form S-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. About Kaltura Kaltura’s mission is to power any video experience for any organization. Our Video Experience Cloud offers live, real-time, and on-demand video products for enterprises of all industries, as well as specialized industry solutions, currently for educational institutions and for media and telecom companies. Underlying our products and solutions is a broad set of Media Services that are also used by other cloud platforms and companies to power video experiences and workflows for their own products. Kaltura’s Video Experience Cloud is used by leading brands reaching millions of users, at home, at school and at work, for communication, collaboration, training, marketing, sales, customer care, teaching, learning, and entertainment experiences. CONTACT: Media Contacts: Kaltura Lisa Bennett email@example.com Headline Media Raanan Loew firstname.lastname@example.org +1 347 897 9276 Investor Contact: Sapphire Investor Relations Erica Mannion and Michael Funari +1 617 542 6180 IR@Kaltura.com
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021. The presentation will be made available for on-demand listening beginning Tuesday, March 9th at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event. About Baudax Bio Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com. CONTACT: Investor Relations Contact:Argot PartnersSam Martin / Claudia Styslinger(212) email@example.com Baudax Bio, Inc.Ryan D. Lake(484) firstname.lastname@example.org Media Contact:Argot PartnersDavid Rosen(212) email@example.com
Acquisition of Leading Sexual Wellness Omni-Channel Retailer Further Solidifies Leadership in Sexual Wellness CategoryLOS ANGELES, March 02, 2021 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (Nasdaq: PLBY) (the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced the completion of its previously announced deal to acquire TLA Acquisition Corp., the parent company of the Lovers family of stores (“Lovers”), a leading omni-channel online and brick-and-mortar sexual wellness chain, with 41 stores in five states. The acquisition of 100% of the equity of Lovers was completed for a purchase price of $25M of cash. Lovers is expected to generate $45M in revenue over the next twelve months, and approximately $5M of Adjusted EBITDA. The deal is immediately accretive to shareholders on a per share basis. Barbara Cook, CEO of Lovers, will join PLBY Group as Executive Vice President, Sexual Wellness working across PLBY Group’s Sexual Wellness brands and product lines, and remain at the helm of Lovers as its Chief Executive Officer. “We are thrilled to officially welcome the Lovers team to PLBY Group. This transaction accelerates our company’s Sexual Wellness growth strategy with a new owned distribution platform, superior merchandising leadership, and strong product innovation capabilities,” said Ben Kohn, CEO of PLBY Group. “Lovers intimacy offerings align with the fastest growing category on our Yandy platform, and Lovers brick-and-mortar and digital retail footprint represents immediate expanded distribution for Playboy-branded Sexual Wellness offerings. While we are not factoring in synergy opportunities today, we expect to drive significant operational efficiencies in a post-Covid world. We also plan to move quickly in a post-Covid environment to aggressively expand Lovers domestically, digitally, and internationally leveraging the Playboy brand’s global awareness and operations.” Mr. Kohn continued, “Most importantly, I couldn’t be more excited to welcome the CEO of Lovers, Barbara Cook, and the whole Lovers team to PLBY Group. Barbara brings with her more than two decades of retail and merchandising leadership experience from retail giants like Gap, Inc. and Starbucks, and we are eager to apply her expertise across our whole company.” “Today is a momentous day for Lovers and the Sexual Wellness industry. I’m immensely proud of the recent growth achieved by our Lovers team, and thrilled to embark on this next chapter as part of PLBY Group, an organization dedicated to helping consumers around the world integrate pleasure into their lives,” said Barbara Cook, CEO of Lovers and newly appointed PLBY Group EVP of Sexual Wellness. “I’m thrilled to join Ben and the whole the PLBY Group organization to build products, services, and retail experiences to lead in the rapidly growing category of Sexual Wellness. I can’t wait to get started.” On February 11, 2021, the Company began trading on Nasdaq Global Market after completing its business combination with Mountain Crest Acquisition Corp. (“MCAC”), a special purpose acquisition company. Upon completing the merger, Mountain Crest Acquisition Corp changed its name to PLBY Group, Inc. and the Company closed the transaction with more than $100 million in unrestricted cash and a newly flexible cap structure. Playboy’s return to the public markets as PLBY Group presents a transformed, streamlined, and high-growth business, including its iconic brand contracted licensing business, owned-and-operated sexual wellness products available for sale on its owned digital commerce platforms in major retail stores in the US, and a growing variety of clothing and branded lifestyle and digital gaming products, including one of the leading men’s apparel businesses in China. About PLBY Group, Inc. PLBY Group, Inc. (“PLBY Group”) connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four major categories: Sexual Wellness, Style & Apparel, Gaming & Lifestyle, and Beauty & Grooming. PLBY Group’s flagship consumer brand, Playboy, is one of the most recognizable, iconic brands in the world, driving more than $3 billion in global consumer spend annually across 180 countries. Learn more at http://www.plbygroup.com. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, growth plans and anticipated financial impacts of the business combination and the Lovers acquisition. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include, but are not limited to: (1) the impact of COVID-19 pandemic on the Company’s business; (2) the inability to maintain the listing of the Company’s shares of common stock on Nasdaq following the business combination; (3) the risk that the business combination or its planned transactions disrupt the Company’s current plans and operations, including the risk that the Company does not complete any such planned transactions or achieve the expected benefit from them; (4) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth profitably, and retain its key employees; (5) costs related to the business combination; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (8) risks relating to the uncertainty of the projected financial information of the Company; (9) risks related to the organic and inorganic growth of the Company’s business and the timing of expected business milestones; and (10) other risks and uncertainties indicated from time to time in the definitive proxy statement relating to the business combination, including those under “Risk Factors” therein, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive, and readers should not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based. Non-GAAP Financial Measures This press release contains certain financial information, data and forecasts, such as Adjusted EBITDA, that have not been prepared in accordance with generally accepted accounting principles (“GAAP”). PLBY Group believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating historical or projected operating results and trends and in comparing PLBY Group's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and revenue that are required by GAAP to be recorded in PLBY Group’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and revenue items are excluded or included in determining these non-GAAP financial measures. For a description of the non-GAAP financial measures referred to herein and reconciliations to the most comparable GAAP financial measure for previously reported periods, please see PLBY Group’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on January 21, 2021 (as supplemented on February 2, 2021) and other reports and documents that it files with or furnishes to the SEC. The Company has not provided a reconciliation of any such forward-looking non-GAAP financial measures because not all of the information necessary for a quantitative reconciliation of the forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures is available without unreasonable efforts at this time. Such information could have a significant impact on the expected comparable GAAP financial measures for the same period. Contact:Investors: firstname.lastname@example.orgMedia: email@example.com
Record 230 honorees for 2020 achieve total 290 million accident-free milesGREENWICH, Conn., March 02, 2021 (GLOBE NEWSWIRE) -- XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, today announced that another ten XPO less-than-truckload (LTL) drivers surpassed three million accident-free miles in the last six months of 2020: Vincent Black (Georgia), Ronald Boring (Tennessee), Craig Boyd (Tennessee), Joe Caliri (Ohio), Marty Collier (Arkansas), Charles Dangerfield (Virginia), Samuel Gleason (Pennsylvania), Dale Pritchett (Texas), Lee Redfearn (North Carolina) and Michael Stirewalt (North Carolina). An additional 16 XPO drivers reached two million accident-free miles and 125 drivers reached one million accident-free miles in the same period, bringing the annual number of honorees to a record 230 drivers for 2020. All are employed by the company’s North American LTL unit. XPO tracks accident-free miles in its LTL network as part of the company’s comprehensive safety program, Road to Zero. On average, it takes approximately a decade of safe driving to achieve one million miles without an accident. Josephine Berisha, chief human resources officer of XPO Logistics, said, “We’re extremely proud of our entire LTL team and their commitment to our safety culture. The high caliber of our drivers and our investments in technology are ensuring that every mile driven for our customers is as productive as possible. We congratulate all of our million-milers for being among the best of the best.” XPO is one of the largest North American providers of LTL transportation, with a national network of 290 service centers and approximately 12,000 professional drivers. About XPO LogisticsXPO Logistics, Inc. (NYSE: XPO) provides cutting-edge supply chain solutions to the most successful companies in the world. The company is the second largest contract logistics provider and the second largest freight broker globally, and a top three less-than-truckload provider in North America. XPO uses a highly integrated network of 1,629 locations and over 100,000 employees in 30 countries to help more than 50,000 customers manage their supply chains most efficiently. The company’s corporate headquarters are in Greenwich, Conn., USA, and its European headquarters are in Lyon, France. Visit xpo.com for more information, and connect with XPO on Facebook, Twitter, LinkedIn, Instagram and YouTube. Media ContactXPO Logistics, Inc.Joe Checklerfirstname.lastname@example.org